Perseus Proteomics, Inc. (JP:4882)
:4882
Want to see JP:4882 full AI Analyst Report?
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥187.00 - ¥478.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.21B
Enterprise Value¥1.42B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-58.44
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsGross margins of ~86%–94% indicate very strong unit economics and pricing power. Sustainably high gross margins mean additional revenue converts largely to gross profit, providing a structural advantage that can support operating leverage and profitability as revenue scales, if fixed costs are controlled.
Debt-free Balance SheetA debt-free capital structure materially reduces refinancing and interest-rate risk, giving management durable financial flexibility. This lowers mandatory cash outflows and preserves optionality to fund R&D or operations via equity or cash, a structural benefit while the company addresses cash burn.
Consistent Revenue GrowthMulti-year revenue growth, including +7.23% in 2025, shows underlying market traction and demand persistence. When paired with high gross margins, steady top-line growth creates a structural pathway to spread fixed costs, improve operating margins, and reduce reliance on financing over the medium term.
Bears Say
Persistent Cash BurnOperating cash flow and free cash flow are materially negative and consistently so, indicating the business consumes significant cash to operate. Persistent cash burn forces dependence on external financing, shortens runway, and is a durable liquidity risk until operations become cash generative.
Deep Negative ProfitabilityA net margin of -752% and materially negative EBIT/EBITDA show the cost base far exceeds revenue today. Such extreme losses imply structural expense or scale deficiencies, making profitability contingent on significant revenue growth or cost restructuring, not a short-term fix.
Eroding Equity And Negative ROEDeclining equity and strongly negative returns on equity signal capital erosion from ongoing losses. Reduced equity weakens the balance-sheet buffer, raising the likelihood of dilution or additional capital raises and reflecting a structural failure to generate returns on invested capital.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥187.00 and its highest was ¥478.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.21B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 95 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on May 14, 2026. The company reported -¥11.03 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.03.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 16,999,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---